↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype

Overview of attention for article published in Clinical Pharmacology & Therapeutics, March 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
7 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
88 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype
Published in
Clinical Pharmacology & Therapeutics, March 2014
DOI 10.1038/clpt.2014.54
Pubmed ID
Authors

J P Clancy, S G Johnson, S W Yee, E M McDonagh, K E Caudle, T E Klein, M Cannavo, K M Giacomini

Abstract

Cystic fibrosis (CF) is a life-shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that potentiates CFTR gating function and is specifically indicated for CF patients with a particular CFTR variant, G551D-CFTR (rs75527207). Here, we provide therapeutic recommendations for ivacaftor based on preemptive CFTR genotype results.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 1%
India 1 1%
Canada 1 1%
Spain 1 1%
United States 1 1%
Unknown 83 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 19%
Student > Ph. D. Student 12 14%
Student > Master 11 13%
Student > Bachelor 10 11%
Student > Postgraduate 7 8%
Other 15 17%
Unknown 16 18%
Readers by discipline Count As %
Medicine and Dentistry 31 35%
Pharmacology, Toxicology and Pharmaceutical Science 13 15%
Biochemistry, Genetics and Molecular Biology 9 10%
Agricultural and Biological Sciences 7 8%
Chemistry 2 2%
Other 3 3%
Unknown 23 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2018.
All research outputs
#3,238,806
of 18,141,016 outputs
Outputs from Clinical Pharmacology & Therapeutics
#666
of 3,721 outputs
Outputs of similar age
#36,080
of 195,815 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#9
of 39 outputs
Altmetric has tracked 18,141,016 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,721 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,815 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.